- Research article
- Open Access
- Open Peer Review
Tumour necrosis factor-alpha expression in tumour islets confers a survival advantage in non-small cell lung cancer
© Ohri et al; licensee BioMed Central Ltd. 2010
- Received: 27 January 2010
- Accepted: 23 June 2010
- Published: 23 June 2010
The role of TNFα in cancer is complex with both pro-tumourigenic and anti-tumourigenic roles proposed. We hypothesised that anatomical microlocalisation is critical for its function.
This study used immunohistochemistry to investigate the expression of TNFα in the tumour islets and stroma with respect to survival in 133 patients with surgically resected NSCLC.
TNFα expression was increased in the tumour islets of patients with above median survival (AMS) compared to those with below median survival (BMS)(p = 0.006), but similar in the stroma of both groups. Increasing tumour islet TNFα density was a favorable independent prognostic indicator (p = 0.048) while stromal TNFα density was an independent predictor of reduced survival (p = 0.007). Patients with high TNFα expression (upper tertile) had a significantly higher 5-year survival compared to patients in the lower tertile (43% versus 22%, p = 0.01). In patients with AMS, 100% of TNFα+ cells were macrophages and mast cells, compared to only 28% in the islets and 50% in the stroma of BMS patients (p < 0.001).
The expression of TNFα in the tumour islets of patients with NSCLC is associated with improved survival suggesting a role in the host anti-tumour immunological response. The expression of TNFα by macrophages and mast cells is critical for this relationship.
- Mast Cell
- Tumour Stroma
- Extended Survival
- Resected NSCLC
- Tumour Islet
Non-small cell lung cancer (NSCLC) is the world's leading cause of cancer related death. At present, the majority of patients present with advanced stages of disease which are not amenable to curative treatment. Even with the optimal presentation of stage Ia disease, the 5-year survival is just 67%  assuming fitness for surgical resection. Currently chemotherapy does not offer cure for patients with NSCLC. Thus, it is vital that new biomarkers of disease and novel therapies are developed. It is now recognised that inflammatory and immune responses play a key role in cancer development and prevention [2, 3] and it hoped that manipulation of these may yield novel therapies in the future.
Tumour necrosis factor-alpha (TNFα) is a key and proximal component of many inflammatory pathways. It plays a key role in host defence to a variety of pathogens [4, 5], but is also implicated in the promotion of many inflammatory diseases [6, 7], including rheumatoid arthritis and inflammatory bowel disease.
The tumour biology of TNFα however is complicated, with evidence of both pro-tumourigenic and anti-tumourigenic activity in animal models [8, 9]. Perhaps the best evidence that the predominant role played by TNFα is anti-tumourigenic arises from studies of anti-TNFα strategies for the treatment of inflammatory disease in man. These show a significant increase in the rate of neoplastic disease in patients receiving active treatment, and no evidence of protection against cancer development [10–16]. The complete resolution of NSCLC in a patient following withdrawal of anti-TNFα therapy is also described . In contrast, the administration of anti-TNFα has had no significant effect on the progression of several advanced cancers [18–20]. Furthermore, recombinant TNFα is a useful and licensed adjunctive treatment for sarcoma and melanoma [21, 22].
There is therefore debate as to whether or not TNFα plays a role in NSCLC tumour cytotoxicity or conversely, tumour progression. Two small studies investigated previously the mRNA or protein expression of TNFα in NSCLC, and suggested overall that TNFα expression was either mildly beneficial but not an independent factor  or neutral , respectively. However, the anatomical localisation of the TNFα expressed was not taken into account. We have shown previously that the site of inflammatory cell infiltration in NSCLC is critical in terms of prognosis. Patients with high expression of macrophages in the tumour islets have extended survival independently of tumour stage, and these macrophages demonstrate high expression of TNFα and other cytotoxic markers, suggesting they are of an anti-tumourigenic cytotoxic M1 macrophage phenotype [25, 26].
This previous work investigating TNFα expression in macrophages was aimed primarily at determining the phenotype of these cells rather than the prognostic significance of TNFα expression. Due to the nature of the work, relatively small numbers of patients were studied. The aim of this study was therefore to assess the prognostic significance of TNFα expression, irrespective of cell type in NSCLC, paying particular attention to its anatomical microlocalisation, in surgically resected NSCLC in our complete cohort of patients described previously .
No. of patients
Age - years
66.3 ± 1.2
65.3 ± 1.2
Male sex - no. (%)
Year of surgery - no. (%)
Tumour stage - no. (%)
3b and 4
Histology - no. (%)
Tumour Grade - no. (%)
Adjuvant Chemotherapy (%)
Palliative Radiotherapy (%)
Survival - months
84.0 ± 5.1
10.8 ± 0.8
Specimens studied were formalin fixed and paraffin embedded. Only blocks containing the advancing edge of the primary tumour were evaluated. Tissue sections of 4 μm thickness were cut onto glass slides and then de-waxed in xylene and rehydrated through graded alcohols. Antigen retrieval was carried out using Trilogy Antigen Retrieval solution (Cell Marque, Hot Springs, United States of America) in a pressure cooker (heated to 117.5°C for 1 min and then cooled to 100°C for 30 seconds). TNFα mouse antihuman antibody was used (clone P/T2; Abcam, Cambridge, United Kingdom). Immunostaining was performed and TNFα was developed with peroxidase and 3,3'-diaminobenzidine tetrahydrochloride (brown reaction product). Sections were then counterstained with haematoxylin and mounted in an aqueous mounting medium (BDH Chemicals Ltd, Poole, United Kingdom). Appropriate isotype controls were performed where the primary antibodies were replaced by irrelevant mouse mAb of the same isotype and at the same concentration as the specific primary mAb. To assess whether TNFα + cells were localised to mast cells, a double-stain technique described previously by us was used [25, 26], with the mouse monoclonal antibody to human tryptase (clone AA1, Dako Cytomation, Ely, Cambridgeshire, United Kingdom) employed to identify mast cells.
Analysis and Validation of Immunostaining
Analysis was performed blind with respect to the clinical outcome. The ten most representative high-power fields (x400) per slide were manually selected using an Olympus BX50 microscope (Olympus, Southall, United Kingdom). The respective areas of stroma and tumour islets were then measured at x400 magnification using Analysis imaging software (Soft Imaging System GmbH). The number of nucleated cells with positive staining for TNFα in each area were then counted manually and expressed as cells/mm2 of stroma or tumour islets. Analysis was repeated for 20 patients to assess repeatability and validity.
Statistical analyses were carried out using the GraphPad Prism software package (v. 4.02; GraphPad Prism Software Inc, San Diego, CA). For categoric analysis, the median value was used as a cut point to dichotomise the series. The χ2 test was used to test for relationships between categoric variables, and the Mann-Whitney nonparametric test was used to compare categoric with continuous variables. The Kruskal-Wallis one-way analysis of variance test was used to compare multiple groups. Kaplan-Meier survival curves were used to look for correlations with survival and were compared with the use of the log-rank statistic. For the above comparisons, p < 0.05 was considered statistically significant. A multivariate Cox proportional hazards model was used to estimate adjusted hazard ratios, 95% CIs, and to identify which of the macrophage markers were independent prognostic factors using the Statistical Package for the Social Sciences (SPSS, v. 13.0; SPSS Inc, Chicago, IL). The validity of the proportional hazards assumption was assessed from log(-log [Survival]) curves.
Patent characteristics are shown in Table 1. Of the 133 patients studied, 110 had died at the time of analysis. Thirty-day mortality for the cohort was 4% and patients who died within the first 60 days of surgery were not included in this analysis. Sixty-eight tumours were squamous, 42 adenocarcinoma, 12 large cell, and 11 other. Sixty were stage I, 37 stage II, 32 stage IIIa, and four stage IIIb or IV. Two patients had additional postoperative chemotherapy and 20 had additional radiotherapy, 16 of whom had it for later palliation. Neither had any effect on survival. The overall 5-year survival was 31.3%.
Validation of Analysis
Kaplan-Meier Survival Analysis
Multivariate Cox Proportional Hazards Analysis
Results of Cox Regression Analysis.
0.989 to 1.000
1.002 to 1.011
1.000 to 1.043
0.077 to 1.035
0.102 to 1.372
IIIb and IV
0.194 to 2.619
Grade - differentiated
0.177 to 1.306
0.488 to 1.159
0.323 to 1.553
0.363 to 1.891
0.235 to 1.640
Cellular localisation of TNFα
Assessment of the percentage of cell types expressing TNFα in patients with NSCLC in above median survival patients in the islets (AMSI) and stroma (AMSS) and below median survival patients in the islets (BMSI) and stroma (BMSS).
% of cells which were Macrophages
% of cells which were mast cells
Estimated % of other cell types
The purpose of this study was to investigate the relationship between the microanatomical expression of TNFα and survival in surgically resected NSCLC. The results demonstrate that expression of TNFα in the tumour islets is associated with a significant increase in 5-year survival, independently of other favorable prognostic factors including stage, and that TNFα expression in the stroma is an independent predictor of reduced survival.
The role of TNFα in tumour biology remains controversial with both pro-tumourigenic and anti-tumourigenic properties identified [8–10, 21, 27]. Two small previous studies of patients with NSCLC suggested TNFα expression had little relationship to clinical outcome, but these did not distinguish between expression in tumour stroma and epithelial islets. The biology of these two tumour compartments demonstrates profound differences in matrix composition, cellular content and vascularity. Our previous studies [25, 26] have demonstrated the importance of anatomical microlocalisation in terms of potential sites for cytotoxicity against tumours. The key findings of these studies was that tumour epithelial islets are the likely site of host cytotoxic responses against tumour progression because patients with extended survival have infiltration of their tumour islets with mast cells and macrophages [25, 26]. Many cytokine-dependent effects are mediated through localized cell-cell contact, including the presentation of membrane-bound TNFα to TNFα-receptor + cells . The effects of cytokines including TNFα on tumour stroma versus islets are therefore likely to vary profoundly depending on the site of release, and the cell-cell interactions between TNFα-producing cells and the cells they interact with. We therefore analysed TNFα expression with close attention to expression in the stroma versus the tumour islets.
In keeping with biological relevance of this concept, patients with AMS survival had greater immunoreactive TNFα expression in their tumour islets compared to those with BMS, and there was a positive correlation between increasing islet TNFα + cell density and survival. In addition, when our patient cohort was divided into tertiles according to islet TNFα + cell density we observed that patients with high expression (upper tertile) had significantly improved 5-year survival. Thus increasing expression of TNFα in the tumour islets was associated with a significant increase in 5-year survival, independently of other favorable prognostic factors. Conversely, although the density of TNFα + cells in the stroma was similar in AMS and BMS patients, TNFα expression in the stroma emerged as an independent predictor of reduced survival following Cox regression analysis. These results indicate that the micro-anatomical location of TNFα expression is potentially critical in determining its role in tumour biology.
Tumour stage is a key determinant of survival following surgery for NSCLC . We were able to show that the relationship between survival and islet TNFα expression was evident within tumour stages although due to the relatively small numbers for each stage the differences did not reach statistical significance. Patients with stage I disease survive longer than patients with stage IIIa disease . However, when tumour islet TNFα expression was compared by stage with respect to survival, it was of note that patients with stage IIIa NSCLC and high TNFα expression had a 5-year survival of 25%, comparable to that of stage I NSCLC patients with low TNFα expression, who had a 5-year survival of 26%. Conversely, patients with stage I NSCLC and high TNFα expression have a 5-year survival of 46%. This suggests that TNFα expression within tumour islets is therefore a key determinant of NSCLC survival within stage, even within early stage disease.
A striking observation from this study was the cellular distribution of TNFα immunoreactivity in the tumour islets of patients with extended survival compared to those with poor survival. The macrophages which infiltrate the tumour islets in NSCLC are predominantly of the M1 cytotoxic phenotype  which express TNFα. We have extended this work in the current study and show that mast cells within the tumour islets also express TNFα. What is striking, however, is that in the subset of patients with extended survival, all TNFα islet immunoreactivity was accounted for by macrophages and mast cells. In the subset of patients with poor survival, TNFα expression in the islets was also evident, but was rarely present in mast cells or macrophages. Thus it is not only expression of TNFα in the tumour islets that is critical in determining survival, but perhaps more importantly, the type of cells which are expressing it.
The distinction of tumour islets versus stroma is important as there is evidence suggesting that TNFα located in the stroma contributes towards tumour proliferation via angiogenesis . In support of this, although there was no difference in the stromal density of TNFα + cells in AMS versus BMS patients, increasing stromal TNFα expression emerged as an independent predictor of worse survival. Whether this is due to the effects of TNFα on the stroma or a reflection of the inability of potentially beneficial TNFα-expressing macrophages and mast cells to infiltrate the islets is not known. The latter could be explained by an inappropriate chemokine repertoire released by the tumour stroma or even by a physical barrier, such as a thickened basement membrane, between the stroma and tumour islets.
The results of this study add to our previous work and have important clinical implications. We have shown that the density of TNFα + cells in tumour islets is a predictor of extended survival in NSCLC following surgery. Its localization to macrophages and mast cells in the tumour islets is the key factor relating to improved prognosis, and it seems unlikely that anti-TNFα strategies will be beneficial to such patients. In contrast, in poor prognosis patients whose tumours contain relatively few TNFα + macrophages and/or mast cells, anti-TNFα strategies may be worthy of further study as stromal expression is an independent predictor of poor survival. In view of the marked microanatomical and immunological heterogeneity within the tumour microenvironment in NSCLC, it is essential that attention is paid to this principle in future immunomodulatory trials in this disease. Targeting subphenotypes of disease with immunopathology predicted to respond to the intervention may then lead to the development of better anti-neoplastic therapeutic strategies.
Funding for this study was provided by the James Maxwell Grant Prophit Fellowship awarded to Dr Chandra Ohri by the Royal College of Physicians, London, United Kingdom.
- Mountain CF: Revisions in the International System for Staging Lung Cancer. Chest. 1997, 111 (6): 1710-1717. 10.1378/chest.111.6.1710.View ArticlePubMedGoogle Scholar
- O'Byrne KJ, Dalgleish AG: Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer. 2001, 85 (4): 473-483. 10.1054/bjoc.2001.1943.View ArticlePubMedPubMed CentralGoogle Scholar
- Dalgleish AG, O'Byrne K: Inflammation and cancer: the role of the immune response and angiogenesis. Cancer Treat Res. 2006, 130: 1-38. full_text.View ArticlePubMedGoogle Scholar
- Mastroeni P, Villarreal-Ramos B, Hormaeche CE: Effect of late administration of anti-TNF alpha antibodies on a Salmonella infection in the mouse model. Microb Pathog. 1993, 14 (6): 473-480. 10.1006/mpat.1993.1046.View ArticlePubMedGoogle Scholar
- Nakane A, Minagawa T, Kato K: Endogenous tumor necrosis factor (cachectin) is essential to host resistance against Listeria monocytogenes infection. Infect Immun. 1988, 56 (10): 2563-2569.PubMedPubMed CentralGoogle Scholar
- Bazzoni F, Beutler B: The tumor necrosis factor ligand and receptor families. N Engl J Med. 1996, 334 (26): 1717-1725. 10.1056/NEJM199606273342607.View ArticlePubMedGoogle Scholar
- Locksley RM, Killeen N, Lenardo MJ: The TNF and TNF Receptor Superfamilies: Integrating Mammalian Biology. Cell. 2001, 104 (4): 487-501. 10.1016/S0092-8674(01)00237-9.View ArticlePubMedGoogle Scholar
- Balkwill F: TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev. 2006, 25 (3): 409-416. 10.1007/s10555-006-9005-3.View ArticlePubMedGoogle Scholar
- Mocellin S, Rossi CR, Pilati P, Nitti D: Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev. 2005, 16 (1): 35-53. 10.1016/j.cytogfr.2004.11.001.View ArticlePubMedGoogle Scholar
- Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006, 295 (19): 2275-2285. 10.1001/jama.295.19.2275.View ArticlePubMedGoogle Scholar
- Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, et al: Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol. 2003, 30 (12): 2563-2571.PubMedGoogle Scholar
- Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al: Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004, 50 (5): 1400-1411. 10.1002/art.20217.View ArticlePubMedGoogle Scholar
- Lipsky PE, van der Heijde DMFM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al: Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis. N Engl J Med. 2000, 343 (22): 1594-1602. 10.1056/NEJM200011303432202.View ArticlePubMedGoogle Scholar
- St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al: Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004, 50 (11): 3432-3443. 10.1002/art.20568.View ArticlePubMedGoogle Scholar
- Stone JH, Holbrook JT, Marriott MA, Tibbs AK, Sejismundo LP, Min YI, et al: Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum. 2006, 54 (5): 1608-1618. 10.1002/art.21869.View ArticlePubMedGoogle Scholar
- van de Putte LBA, Atkins C, Malaise M, Sany J, Russell AS, van Riel PLCM, et al: Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004, 63 (5): 508-516. 10.1136/ard.2003.013052.View ArticlePubMedPubMed CentralGoogle Scholar
- Lees CW, Ironside J, Wallace WA, Satsangi J: Resolution of non-small-cell lung cancer after withdrawal of anti-TNF therapy. N Engl J Med. 2008, 359 (3): 320-321. 10.1056/NEJMc0800250.View ArticlePubMedGoogle Scholar
- Brown ER, Charles KA, Hoare SA, Rye RL, Jodrell DI, Aird RE, et al: A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. Ann Oncol. 2008, 19 (7): 1340-1346. 10.1093/annonc/mdn054.View ArticlePubMedGoogle Scholar
- Du Bois JS, Trehu EG, Mier JW, Shapiro L, Epstein M, Klempner M, et al: Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma. J Clin Oncol. 1997, 15 (3): 1052-1062.PubMedGoogle Scholar
- Tsimberidou AM, Waddelow T, Kantarjian HM, Albitar M, Giles FJ: Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNF alpha levels during treatment. Leuk Res. 2003, 27 (5): 375-380. 10.1016/S0145-2126(02)00082-6.View ArticlePubMedGoogle Scholar
- Lejeune FJ, Ruegg C: Recombinant human tumor necrosis factor: an efficient agent for cancer treatment. Bull Cancer. 2006, 93 (8): E90-100.PubMedGoogle Scholar
- Lejeune FJ, Lienard D, Matter M, Ruegg C: Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun. 2006, 6: 6-PubMedGoogle Scholar
- Boldrini L, Calcinai A, Samaritani E, Pistolesi F, Mussi A, Lucchi M, et al: Tumour necrosis factor-[agr] and transforming growth factor-[bgr] are significantly associated with better prognosis in non-small cell lung carcinoma: putative relation with BCL-2-mediated neovascularization. Br J Cancer. 2000, 83 (4): 480-486. 10.1054/bjoc.2000.1345.View ArticlePubMedPubMed CentralGoogle Scholar
- Tran TA, Kallakury BV, Ambros RA, Ross JS: Prognostic significance of tumor necrosis factors and their receptors in nonsmall cell lung carcinoma. Cancer. 1998, 83 (2): 276-282. 10.1002/(SICI)1097-0142(19980715)83:2<276::AID-CNCR11>3.0.CO;2-Q.View ArticlePubMedGoogle Scholar
- Ohri CM, Shikotra A, Green RH, Waller DA, Bradding P: Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. Eur Respir J. 2009, 33 (1): 118-126. 10.1183/09031936.00065708.View ArticlePubMedGoogle Scholar
- Welsh TJ, Green RH, Richardson D, Waller DA, O'Byrne KJ, Bradding P: Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol. 2005, 23 (35): 8959-8967. 10.1200/JCO.2005.01.4910.View ArticlePubMedGoogle Scholar
- Balkwill F: Tumor necrosis factor or tumor promoting factor?. Cytokine & Growth Factor Reviews. 2002, 13 (2): 135-141. 10.1016/S1359-6101(01)00020-X.View ArticleGoogle Scholar
- Chen G, Goeddel DV: TNF-R1 Signaling: A Beautiful Pathway. Science. 2002, 296 (5573): 1634-1635. 10.1126/science.1071924.View ArticlePubMedGoogle Scholar
- Szlosarek P, Charles KA, Balkwill FR: Tumour necrosis factor-alpha as a tumour promoter. Eur J Cancer. 2006, 42 (6): 745-750. 10.1016/j.ejca.2006.01.012.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://0-www.biomedcentral.com.brum.beds.ac.uk/1471-2407/10/323/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.